EXBLIFEP
Growthcefepime hydrochloride; enmetazobactam
NDAINTRAVENOUSPOWDERPriority Review
Approved
Feb 2024
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
3/8 — Basic
Priority Review
EXBLIFEP (cefepime hydrochloride; enmetazobactam). Approved for the treatment of pneumonia (moderate to severe) caused by susceptible strains of streptococcus pneumoniae, including cases associated with concurrent bacteremia, pseudomonas aeruginosa and 15 more indications. First approved in 2024.
Drug data last refreshed 3d ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EXBLIFEP is a fixed-dose combination of cefepime hydrochloride and enmetazobactam, a novel beta-lactam/beta-lactamase inhibitor IV antibiotic. It treats moderate-to-severe pneumonia, complicated urinary tract infections, complicated skin infections, and complicated intra-abdominal infections caused by susceptible gram-negative and gram-positive pathogens. The enmetazobactam component inhibits beta-lactamases to restore cefepime's activity against resistant organisms.
Growth8.5 years to LOE
Recent 2024 approval positions EXBLIFEP in early growth phase with opportunity to build market share against established competitors; commercial team expansion likely in sales, marketing, and market access.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.